APEIRON Biologics: Patient recruitment completed in Phase II COVID-19 Clinical Trial of APN01

• Results of the double-blind, placebo-controlled trial expected in Q1 2021
• Preparations for rolling Marketing Authorization Application in Europe commenced
• Trial results to confirm unique triple mode of action to prevent infection, organ injury and inflammation

Press release (EN) | Presseaussendung (DE)